FrancophonIA/ELRC3.0 huggingface dataset:
English: When given together, their actions reduce appetite and the amount that patients eat, and increase energy expenditure, helping them to stick to a calorie-controlled diet and to reduce their body weight.
Croatian: Ako se primjenjuju zajedno, njihovo djelovanje smanjuje apetit i količinu hrane koju bolesnik jede, a povećava potrošnju energije, pomažući bolesnicima da se pridržavaju prehrane s kontroliranim unosom kalorija te na taj način smanje svoju tjelesnu težinu.
English: • who are overweight (have a BMI between 27 and 30) and have weight-related complications such as diabetes, abnormally high levels of fat in the blood, or high blood pressure.
Croatian: • s prekomjernom tjelesnom težinom (imaju ITM između 27 i 30) uz prisutnost najmanje jednog komorbiditeta povezanog s tjelesnom težinom kao što je dijabetes, abnormalno visoke razine masti u krvi ili visoki krvni tlak.
English: The degree of improvement with Mysimba over placebo was similar using different methods of analysis, although the benefits were smallest with the most conservative methods that assumed patients who did not complete the study would not have seen any improvement.
Croatian: Stupanj poboljšanja s lijekom Mysimba u odnosu na placebo bio je sličan primjenom različitih metoda analize, iako su koristi bile najmanje u slučaju najkonzervativnijih metoda koje su pretpostavile da bolesnik koji nije završio ispitivanje ne bi bio uočio ikakvo poboljšanje.
English: Mysimba contains the active substances naltrexone and bupropion, which are licensed individually in the EU for other uses.
Croatian: Mysimba sadrži djelatne tvari naltrekson i bupropion, koje su svaka zasebno odobrene za druge primjene u EU-u.
English: In the other study, in which patient counselling was also more intensive, the overall weight loss was greater over the study period: 8.1% with Mysimba and 4.9% with placebo.
Croatian: U drugom ispitivanju, u kojem je savjetovanje bolesnika bilo intenzivnije, ukupan gubitak tjelesne težine bio je veći tijekom razdoblja ispitivanja: 8,1% s lijekom Mysimba i 4,9% s placebom.
English: The exact way that Mysimba works is not fully understood, but the two active substances, naltrexone and bupropion, act on the parts of the brain that control food intake and energy balance, as well as reducing the effect of the part of the brain that controls the pleasure associated with eating food.
Croatian: Točan način djelovanja lijeka Mysimba u gubitku tjelesne težine nije u potpunosti poznat, no dvije djelatne tvari, naltrekson i bupropion, djeluju na dio mozga koji kontrolira unos hrane i ravnotežu energije, kao i smanjujući djelovanje na dio mozga koji kontrolira osjećaj zadovoljstva povezan s unosom hrane.
English: Regarding safety, although the CHMP had some concerns about possible effects on the heart and blood vessels (cardiovascular outcomes) and a slightly increased risk of seizures (fits), the most common side effects were largely manageable, as patients could stop taking the medicine if they were bothersome.
Croatian: Vezano uz sigurnost, iako je CHMP imao razloga za zabrinutost o mogućem djelovanju na srce i krvne žile (kardiovaskularne ishode) i neznatno povišen rizik od napadaja, najčešće nuspojave su uglavnom upravljive, budući da su bolesnici mogli prestati uzimati lijek ako su se osjećali preopterećeni.
English: A risk management plan has been developed to ensure that Mysimba is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Mysimba.
English: In addition, the company that markets Mysimba will produce an information pack for doctors prescribing the medicine, including guidance on stopping treatment in patients who do not respond or if there are concerns about side effects.
Croatian: Nadalje, tvrtka koja stavlja lijek Mysimba u promet dostavit će informacijski paket za liječnike koji propisuju lijek, uključujući smjernice o prekidanju terapije u bolesnika koji nisu odgovorili na lijek ili koji su bili zabrinuti zbog nuspojava.
English: What are the risks associated with Mysimba?
Croatian: Koji su rizici povezani s lijekom Mysimba?
English: Mysimba should also be stopped if patients have not lost at least 5% of their initial body weight after 4 months of treatment.
Croatian: Terapiju lijekom Mysimba treba također prekinuti, ako bolesnici nisu izgubili najmanje 5% svoje početne tjelesne težine.
English: Patients in the studies were given the medicine as part of a weight loss programme involving counselling and advice on diet and exercise.
Croatian: Bolesnicima je u ispitivanju dan lijek kao dio programa za smanjivanje tjelesne težine koji je obuhvaćao savjetovanje i savjete o prehrani i tjelovježbi.
English: In three of the studies, the average weight loss in patients treated with Mysimba was around 3.7 to 5.7%, compared with 1.3 to 1.9% with placebo; the proportion of Mysimba-treated patients who achieved 5% weight loss ranged from 28 to 42% compared with 12 to 14% with placebo.
Croatian: U tri provedena ispitivanja, prosječan gubitak tjelesne mase u bolesnika liječenih lijekom Mysimba bio je otprilike 3,7 do 5,7% u usporedbi s 1,3 do 1,9% s placebom; omjer bolesnika liječenih lijekom Mysimba koji su postigli gubitak tjelesne mase do 5% iznosio je 28 do 42% u usporedbi s 12 do 14% s placebom.
English: Mysimba is a medicine used along with diet and exercise to help manage weight in adults:
Croatian: Mysimba je lijek koji se koristi kao dodatak dijeti i povećanoj fizičkoj aktivnosti za kontrolu tjelesne težine u odraslih bolesnika:
English: The effects of Mysimba in reducing body weight have been shown in 4 main studies involving around 4,500 obese or overweight patients, in which Mysimba was compared with placebo (a dummy treatment).
Croatian: Djelovanje lijeka Mysimba u smanjivanju tjelesne težine utvrđeno je u 4 glavna ispitivanja koja su obuhvatila otprilike 4.5000 pretilih bolesnika ili bolesnika s prekomjernom težinom, u kojih je lijek Mysimba uspoređen s placebom (prividnim liječenjem).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Mysimba, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Mysimba nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: About 13 to 22% of those taking Mysimba achieved at least a 10% reduction in weight, while 5 to 6% of placebotreated patients did so.
Croatian: Otprilike 13 do 22% bolesnika koji su uzimali lijek Mysimba postiglo je smanjenje tjelesne težine od najmanje 10%, dok je isto uspjelo samo 5 do 6% bolesnika koji su liječeni placebom.
English: On the balance of the available evidence the CHMP decided that Mysimba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: CHMP odlučio je da koristi od lijeka Mysimba nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: For more information about treatment with Mysimba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Mysimba pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Some 46% and 30% of patients given Mysimba achieved 5 and 10% weight reductions respectively, compared with 34% and 17% respectively with placebo.
Croatian: Otprilike 46% i 30% bolesnika koji su uzimali lijek Mysimba postiglo je smanjenje tjelesne mase od 5 i 10% u usporedbi s 34% i 17% s placebom.
English: How does Mysimba work?
Croatian: Kako djeluje Mysimba?
English: Mysimba must not be used in certain patients at particular risk of side effects, including patients with severely reduced kidney or liver function, those with high blood pressure that is not under control,
Croatian: Mysimba se ne smije koristiti u određenih bolesnika koji su izloženi posebnom riziku od nuspojava, uključujući bolesnike s ozbiljno smanjenom funkcijom bubrega ili jetre, onih s visokim krvnim tlakom koji nije kontroliran, osoba koje su bilo kada imale napadaje, određene psihološke probleme ili koje su imale tumor na mozgu ili prolaze odvikavanje od alkohola ili određenih droga.
English: For practical information about using Mysimba, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Mysimba pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: What benefits of Mysimba have been shown in studies?
Croatian: Koje su koristi lijeka Mysimba utvrđene u ispitivanjima?
English: How is Mysimba used?
Croatian: Kako se Mysimba koristi?
English: Patients should have their response and tolerability to the medicine checked regularly and treatment should be stopped in patients who have certain side effects such as an increase in blood pressure.
Croatian: Terapiju treba prekinuti u bolesnika koji imaju određene nuspojave poput povišenje krvnoga tlaka.
English: For the full list of all side effects reported with Mysimba, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Mysimba potražite u uputi o lijeku.
English: Date of first authorisation: 06/11/2017.
Croatian: Datum prvog odobrenja: 06/11/2017.
English: Pregnancy and lactation: Do not use in pregnant cats.
Croatian: Graviditet i laktacija: Ne primjenjivati u gravidnih mačaka.
English: Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Croatian: Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju : 2 godine.
English: Do not mix with any other veterinary medicinal products except FELIGEN RCP or FELIGEN CRP.
Croatian: Ne miješati s bilo kojim drugim veterinarsko-medicinskim proizvodom, osim s FELIGEN RCP ili FELIGEN CRP.
English: Nobivac LeuFel suspension for injection for cats
Croatian: Nobivac LeuFel, suspenzija za injekciju za mačke
English: After the second injection, and subsequent administrations, this reaction is markedly reduced.,
Croatian: Nakon druge primjene kao i svih narednih, ova reakcija je znatno umanjena.
English: No adverse reactions were observed after an overdose administration of the veterinary medicinal product other than those mentioned in section 6, except local reactions that can last longer (from 5 to 6 weeks at the most).
Croatian: Nakon predoziranja veterinarsko-medicinskim proizvodom nisu opažene druge nuspojave do onih već spomenutih u dijelu 6, osim lokalnih reakcija koje mogu trajati duže (najviše 5-6 tjedana).
English: Primary vaccination: - first injection in kittens from eight weeks of age - second injection 3 or 4 weeks later.
Croatian: - prva primjena mačićima starijim od 8 tjedana - druga primjena 3 ili 4 tjedna kasnije
English: Box of 10 or 50 vials
Croatian: KUTIJA S 10 ILI 50 BOČICA
English: The vaccine contains the purified p45 FeLV-envelope antigen, obtained by genetic recombination of the E. coli strain.
Croatian: Cjepivo sadrži pročišćeni antigen omotača p45 FeLV virusa dobiven genetskim rekombiniranjem soja E. coli.
English: 1ère avenue 2065 m LID 06516 Carros France
Croatian: 1ère avenue 2065 m LID 06516 Carros FRANCUSKA
English: Administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.
Croatian: Aplicirajte subkutano jednu dozu (1 ml) veterinarsko medicinskog proizvoda sukladno sljedećem režimu cijepljenja.
English: Veterinary medicinal product subject to prescription.
Croatian: Veterinarsko-medicinski proizvod se izdaje na recept.
English: Adjuvants: 3% aluminium hydroxide gel expressed as mg Al
Croatian: 3% aluminijev hidroksid gel (izraženo u mg Al
English: The transient signs following vaccination such as hyperthermia (lasting 1 to 4 days), apathy and digestive disturbances may also be commonly observed.
Croatian: Također se mogu opaziti i uobičajeni prolazni simptomi nakon cijepljenja poput hipertermije (traje 1 do 4 dana), apatije (ravnodušnost) i probavnih smetnji (bolovi u trbuhu).
English: Adjuvants: 3% aluminium hydroxide gel expressed as mg Al3+
Croatian: Adjuvans: 3% aluminijev hidroksid gel (izraženo u mg Al3+):
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP or FELIGEN RCP.
Croatian: Dostupni podaci o neškodljivosti i djelotvornosti pokazuju da se ovo cjepivo može primijeniti pomiješan s FELIGEN CRP ili FELIGEN RCP.
English: ère avenue 2065 m LID 06516 Carros France
Croatian: ère avenue 2065 m LID 06516 Carros FRANCUSKA
English: Sodium chloride Disodium phosphate anhydrous Potassium dihydrogen phosphate Aluminium hydroxide gel Quillaja saponaria Water for injections
Croatian: Dinatrijev hidrogen fosfat bezvodni Kalijev dihidrogen fosfat Aluminijev hidroksid gel Quillaja saponaria.
English: PSUR submissions for Nobivac LeuFel shall be synchronised and submitted at the same frequency as for LEUCOGEN.
Croatian: PSUR-evi za Nobivac LeuFel uskladit će se i podnosit jednako često kao i za VMP Leucogen.
English: C/Josefa Valcárcel n°38 28027 Madrid, Spain
Croatian: MSD Animal Health, S.L. C/Josefa Valcárcel n°38 28027 Madrid, Spain
English: Active substance: Minimum quantity of purified p45 FeLV-envelope antigen 102 µg
Croatian: Djelatna tvar: Najmanja količina pročišćenog antigena omotača p45 FeLV 102 µg
English: No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Croatian: 4.10 Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Nakon predoziranja (dvije doze) veterinarsko-medicinskim proizvodom nisu opažene druge nuspojave do onih već spomenutih u dijelu 4.6, osim lokalnih reakcija koje mogu trajati duže (najviše 5-6 tjedana).
English: Active substance: Minimum quantity of purified p45 FeLV-envelope antigen
Croatian: Djelatna tvar: Najmanja količina pročišćenog antigena omotača p45 FeLV:
English: 4.2 Indications for use, specifying the target species
Croatian: KLINIČKE POJEDINOSTI 4.1 Ciljne vrste životinja Mačke 4.2 Indikacije za primjenu, navesti ciljne vrste životinja
English: MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČI ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
English: Vial label
Croatian: ETIKETA NA BOČICI
English: Excipients: Buffered isotonic solution to
Croatian: Pomoćna tvar: Izotonična puferska otopina do
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Croatian: UPUTA O VMP Nobivac LeuFel, suspenzija za injekciju za mačke NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE SERIJE U PROMET, AKO JE RAZLIČITO
English: Marketing authorisation holder and manufacturer responsible for the batch release
Croatian: Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za puštanje serije u promet: Virbac,
English: Excipients: Buffered isotonic solution to 1 ml.
Croatian: Pomoćna tvar: Izotonična puferska otopina do:
English: CLINICAL PARTICULARS
Croatian: Natrijev klorid
English: VIRBAC
Croatian: NUSPOJAVE
English: ivabradine
Croatian: ivabradin
English: In stable angina, these symptoms occur during physical effort.
Croatian: U slučaju stabilne angine ti se simptomi pojavljuju tijekom fizičkog napora.
English: It is used in combination with standard therapy which can include a beta-blocker.
Croatian: Primjenjuje se u kombinaciji sa standardnom terapijom, koja može uključivati beta-blokatore.
English: Also, the doctor should consider stopping treatment if the medicine has only a limited effect on reducing symptoms or reducing the heart rate.
Croatian: Također, liječnik treba razmisliti o prekidu liječenja ako lijek ima samo ograničeni učinak na smanjenje simptoma ili smanjenje brzine otkucaja srca.
English: The recommended starting dose is 5 mg twice a day with meals, which the doctor may increase to 7.5 mg twice a day or decrease to 2.5 mg (half a 5-mg tablet) twice a day depending on the patient's heart rate and symptoms.
Croatian: Preporučena početna doza jest 5 mg dva puta na dan uz obrok, koju liječnik može povećati na 7,5 mg dva puta na dan ili smanjiti na 2,5 mg (pola tablete od 5 mg) dva puta na dan ovisno o brzini srčanih otkucaja i simptomima bolesnika.
English: When used for angina, treatment should be stopped if symptoms do not improve after 3 months.
Croatian: Kad se primjenjuje u bolesnika s anginom, liječenje je potrebno prekinuti ako ne dođe do poboljšanja simptoma nakon tri mjeseca.
English: When this current is blocked, the heart rate is lowered, so that the heart has less work to do and needs less oxygenated blood.
Croatian: Kad je ta struja blokirana, brzina otkucaja srca smanjuje se tako da srce mora manje raditi i treba manje oksigenirane krvi.
English: The full EPAR for Ivabradine JensonR can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito europsko javno izvješće o procjeni (EPAR) za lijek Ivabradine JensonR nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is used either in patients who cannot take beta-blockers (another type of medicine to treat angina) or in combination with a beta-blocker in patients whose disease is not controlled by a beta-blockers alone.
Croatian: Primjenjuje se u bolesnika koji ne mogu uzimati beta-blokatore (druga vrsta lijeka za liječenje angine) ili u kombinaciji s beta-blokatorima u bolesnika čija se bolest ne kontrolira samo primjenom beta-blokatora.
English: Ivabradine JensonR is available as tablets (5 and 7.5 mg) and can only be obtained with a prescription.
Croatian: Lijek Ivabradine JensonR dostupan je u obliku tableta (od 5 i 7,5 mg) i izdaje se samo na recept.
English: Treatment must be stopped if the heart rate decreases persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue.
Croatian: Liječenje se mora prekinuti ako se brzina otkucaja srca stalno smanjuje na razinu nižu od 50 otkucaja u minuti ili ako se nastave simptomi bradikardije (spora brzina otkucaja srca).
English: This means that Ivabradine JensonR is similar to a ‘reference medicine' already authorised in the European Union (EU) called Procoralan.
Croatian: To znači da je lijek Ivabradine JensonR sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Procoralan.
English: The medicine is used in patients with a normal heart rhythm whose heart rate is at least 70 beats per minute.
Croatian: Lijek se primjenjuje u bolesnika s normalnim srčanim ritmom čija brzina srčanih otkucaja iznosi najmanje 70 otkucaja u minuti.
English: Ivabradine JensonR is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (heart disease caused by blockage of the blood vessels that supply the heart muscle).
Croatian: Ivabradine JensonR je lijek za srce koji se primjenjuje za simptomatsko liječenje kronične stabilne angine (bol u prsnom košu, čeljusti i leđima koja je uzrokovana fizičkim naporom) u odraslih osoba s bolešću koronarnih arterija (bolest srca koju uzrokuje opstrukcija krvnih žila koje opskrbljuju srčani mišić).
English: Ivabradine JensonR therefore reduces or prevents the symptoms of angina.
Croatian: Stoga lijek Ivabradine JensonR smanjuje ili sprečava simptome angine.
English: Ivabradine JensonR is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) and a normal heart rhythm whose heart rate is at least 75 beats per minute.
Croatian: Lijek Ivabradine JensonR također se primjenjuje u bolesnika s kroničnim zatajenjem srca (kad srce ne može opskrbiti ostatak tijela dovoljnom količinom krvi) i normalnim srčanim ritmom čija je brzina srčanih otkucaja najmanje 75 otkucaja u minuti.
English: By lowering the heart rate, Ivabradine JensonR reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Croatian: Snižavanjem brzine otkucaja srca lijek Ivabradine JensonR smanjuje pritisak na srce i time usporava napredak zatajenja srca i poboljšava simptome.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivabradine JensonR have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Ivabradine JensonR nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ivabradine JensonR has been shown to have comparable quality and to be bioequivalent to Procoralan.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, lijek Ivabradine JensonR dokazao usporedivu kakvoću te da je bioekvivalentan lijeku Procoralan.
English: This is a summary of the European public assessment report (EPAR) for Ivabradine JensonR.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Ivabradine JensonR.
English: Because Ivabradine JensonR is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je lijek Ivabradine JensonR generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: What measures are being taken to ensure the safe and effective use of Ivabradine JensonR?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ivabradine JensonR?
English: For more information about treatment with Ivabradine JensonR, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Ivabradine JensonR pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: Therefore, the CHMP's view was that, as for Procoralan, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a da korist nadmašuje identificiran rizik, kao i za lijek Procoralan.
English: Because Ivabradine JensonR is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Procoralan.
Croatian: Budući da je Ivabradine JensonR generički lijek, ispitivanja na bolesnicima bila su ograničena na utvrđivanje činjenice je li lijek bioekvivalentan referentnom lijeku Procoralan.
English: It is not intended to provide practical advice on how to use Ivabradine JensonR.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Ivabradine JensonR.
English: What is Ivabradine JensonR and what is it used for?
Croatian: Što je Ivabradine JensonR i za što se koristi?
English: The Committee recommended that Ivabradine JensonR be approved for use in the EU.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Ivabradine JensonR u EU-u.
English: The symptoms of heart failure are caused by the heart not pumping enough blood around the body.
Croatian: Do simptoma zatajenja srca dolazi ako srce ne opskrbljuje tijelo dovoljnom količinom krvi.
English: For practical information about using Ivabradine JensonR, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Ivabradine JensonR bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.